PD-(L)1 inhibitors
2 abstracts
Abstract
PD-(L)1 inhibitors plus anlotinib: A superior option for second-line treatment of extensive-stage small cell lung cancer.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical University,
Abstract
Effect of KDR mutations on efficacy of immune checkpoint inhibitors in patients with bladder cancer.Org: Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Jinan, Shandong Suncadia Medicine, China National Biotec Group, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd.,